LONGMONT, Colo. & WALTHAM, Mass.--(BUSINESS WIRE)--KromaTiD and SeQure Dx announced today a partnership to market a comprehensive and integrated analysis of off-target gene editing in support of cell and gene therapy research, Investigational New Drug (IND) applications and drug product development.

LONGMONT，Colo。和WALTHAM，Mass。-（BUSINESS WIRE）-KromaTiD和Seque Dx今天宣布建立合作伙伴关系，销售全面和综合的脱靶基因编辑分析，以支持细胞和基因治疗研究，研究新药（IND）应用和药品开发。

The combination of SeQure Dx’s NoteSeQ™ and ScopeSeQ™ platforms with KromaTiD's dGH in-Site™, dGH SCREEN™ and Genomic Integrity Karyotyping™ services provides the world’s first comprehensive, one-stop gene editing evaluation solution..

SeQure Dx的NoteSeQ的组合™和ScopeSeQ™具有KromaTiD dGH的平台™,dGH屏幕™和基因组完整性核型分析™服务提供世界上第一个全面的一站式基因编辑评估解决方案。。

Dr. Keith Joung, Scientific Founder of SeQure Dx, states, 'This joint offering provides a package that will empower scientists to predict and measure outcomes of gene editing across multiple platforms with the goal of minimizing risks to patients from the design stages and ultimately into the clinic.'.

Seque Dx的科学创始人Keith Joung博士表示，“这项联合提供的软件包将使科学家能够预测和测量跨多个平台的基因编辑结果，目的是最大限度地降低设计阶段患者的风险，最终进入诊所“。

Dr. Douglas Smith, Sr. VP Research & Development at SeQure Dx, states, “This partnership creates a powerful solution for developers of genome editing therapies by combining SeQure’s best in class off-target nomination and confirmation platforms with KromaTiD’s superior technologies for unbiased genome-wide rearrangement detection.”.

Sequere Dx的副总裁Douglas Smith博士表示：“这种合作关系为基因组编辑疗法的开发者创造了一个强大的解决方案，将Sequere一流的脱靶提名和确认平台与KromaTiD的卓越技术相结合，实现了无偏见的全基因组重排检测“。

KromaTiD has developed a menu of commercial products and services providing cell and gene therapy developers with unique assays for verification of off-target editing, transgene insertion and edit-associated structural variation. “By using the power of SeQure Dx’s predictive, personalized ONE-seq bioinformatics to design our dGH in-Site assays, researchers can not only confirm the outcomes of gene editing in the genome most relevant to the patient population,” says Christopher Tompkins, KromaTiD’s Chief Technology Officer.

KromaTiD开发了一系列商业产品和服务，为细胞和基因治疗开发人员提供独特的检测方法，用于验证脱靶编辑，转基因插入和编辑相关的结构变异。KromaTiD的首席技术官克里斯托弗·汤普金斯（Christopher Tompkins）说：“通过利用SeQure Dx预测性，个性化的ONE-seq生物信息学的功能来设计我们的dGH现场检测，研究人员不仅可以确认与患者群体最相关的基因组中基因编辑的结果。官员。

“They can then use this data to optimize their editing system, reduce off-target effects, and ultimately improve the safety of the drug product for the benefit of patients.”.

“然后，他们可以使用这些数据来优化编辑系统，减少脱靶效应，最终提高药品的安全性，为患者带来好处。”。

Joung and Tompkins emphasize that experts from each company will work collaboratively with investigators to create and execute a customized study plan including selection of the best combination of assays and analytics to deliver a comprehensive dataset and to support their regulatory filings. The combined offering from SeQure Dx and KromaTiD includes:.

Joung和Tompkins强调，每家公司的专家将与调查人员合作，制定和执行定制的研究计划，包括选择分析和分析的最佳组合，以提供全面的数据集并支持其监管文件。SeQure Dx和KromaTiD的组合产品包括：。

NoteSeQ: Guide Selection, Guide Design, and IND Service – Leveraging the ONE-seq assay to biochemically nominate and illuminate off-target risks and develop mitigation strategies with greater sensitivity and breadth across populations than any other assay

NoteSeQ：指南选择，指南设计和IND服务-利用ONE-seq分析方法进行生物化学提名和阐明脱靶风险，并制定比其他任何分析方法具有更高灵敏度和广度的缓解策略

ScopeSeQ: Editing System Assessments, and IND Services – to confirm and verify off-target gene editing findings

ScopeSeQ：编辑系统评估和IND服务-确认和验证脱靶基因编辑结果

dGH in-Site: Direct, single-cell visualization of the structure of on- and off-target DNA edit sites and mapping of transgene insertions anywhere in the genome

现场dGH：直接，单细胞可视化的on和off目标DNA编辑位点的结构和基因组中任何地方的转基因插入的映射

dGH SCREEN: Single cell, unbiased and ultra-high-resolution mapping of structural variants as small as 2 kb

dGH屏幕：小至2 kb的结构变体的单细胞，无偏和超高分辨率映射

Genomic Integrity Karyotyping: Confirmatory mapping of low prevalence, edit-associated chromosomal structural variation, identification of sub-clonal cell populations and monitoring of cell and gene therapy batch stability

基因组完整性核型分析：低流行率的验证性作图，编辑相关的染色体结构变异，亚克隆细胞群的鉴定以及细胞和基因治疗批次稳定性的监测

For more information about SeQure Dx and KromaTiD as well as updates on this partnership, please visit their respective websites at KromaTiD.com and SeQure-Dx.com.

有关SeQure Dx和KromaTiD的更多信息以及此合作伙伴关系的最新信息，请访问他们各自的网站KromaTiD.com和SeQure-Dx.com。

About SeQure Dx

关于SeQure Dx

SeQure Dx is a genomics intelligence company dedicated to the advancement of on-target gene editing and cell therapies from discovery to patient. SeQure’s initial preclinical platforms for the biopharma industry, NoteSeQ and ScopeSeQ, comprise a suite of proprietary, best-in-class diagnostic assays and bioinformatic analytics that span the spectrum of off-target nomination and confirmation.

SeQure Dx是一家基因组智能公司，致力于从发现到患者的目标基因编辑和细胞疗法的发展。Sequere最初的生物制药行业临床前平台NoteSeQ和ScopeSeQ包含一套专有的，一流的诊断分析和生物信息学分析，涵盖了脱靶提名和确认范围。

The NoteSeQ and ScopeSeQ platforms comprehensively solve our partners’ preclinical off-target evaluation needs, including guide selection and IND submissions. SeQure Dx’s goal is to ensure that gene editing and cell therapies are suitable for all patients who would benefit from this next generation of life-saving technologies.

NoteSeQ和ScopeSeQ平台全面解决了我们合作伙伴的临床前脱靶评估需求，包括指南选择和IND提交。Seque Dx的目标是确保基因编辑和细胞疗法适用于所有将从下一代救生技术中受益的患者。

For more information, please visit sequre-dx.com..

欲了解更多信息，请访问sequre dx.com。。

About KromaTiD, Inc

KromaTiD公司

KromaTiD supports research teams in academia, large pharmaceutical, and therapeutic companies with expert scientific support and unparalleled genomics tools and services. We are your partner for biomarker discovery, genomic integrity analysis of engineered cell products, clone screening, structural genomic assessment and plasmid manufacturing.

KromaTiD通过专家科学支持和无与伦比的基因组学工具和服务，为学术界，大型制药和治疗公司的研究团队提供支持。我们是您的生物标志物发现，工程细胞产品的基因组完整性分析，克隆筛选，结构基因组评估和质粒制造的合作伙伴。

KromaTiD.com.

KromaTiD.com。

For more information about SeQure Dx and KromaTiD and updates on this partnership, please visit their respective websites at KromaTiD.com and SeQure-Dx.com.

有关SeQure Dx和KromaTiD的更多信息以及此合作伙伴关系的更新，请访问他们各自的网站KromaTiD.com和SeQure-Dx.com。